Related references
Note: Only part of the references are listed.Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories
Margherita Perricone et al.
ONCOTARGET (2017)
Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera
Cecilie Utke Rank et al.
LEUKEMIA & LYMPHOMA (2016)
A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR
H. White et al.
LEUKEMIA (2015)
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations
Anthony J. Bench et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study
J. V. Jovanovic et al.
LEUKEMIA (2013)
Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA
Helen E. White et al.
BLOOD (2010)
Concordance of assays designed for the quantification of JAK2V617F: a multicenter study
Eric Lippert et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2V617F
S. Hermouet et al.
LEUKEMIA (2007)
The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders
Thomas Stauffer Larsen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera
Eric Lippert et al.
BLOOD (2006)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes et al.
BLOOD (2006)
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders
F Passamonti et al.
BLOOD (2006)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
An Italian program of external quality control for quantitative assays based on real-time PCR with Taq-Man (TM) probes
CC Raggi et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2005)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
